Journal Article
Montmorency tart cherry (Prunus cerasus L.) concentrate lowers uric acid, independent of plasma cyanidin-3-O-glucosiderutinoside
[2014]
Bell, Phillip G.;
David C. Gaze;
Gareth W. Davison;
Glyn Howatson;
et al.
Montmorency tart cherry (Prunus cerasus L.) concentrate lowers uric acid, independent of plasma cyanidin-3-O-glucosiderutinoside
2014
Bell, Phillip G.; David C. Gaze; Gareth W. Davison; Glyn Howatson; Michael J. Scotter; Trevor W. George
https://doi.org/10.1016/j.jff.2014.09.004
Two doses (30 and 60âmL) of Montmorency tart cherry concentrate (MC) were used to investigate their impact on physiological indices of uric acid activity, inflammation and the bioavailability of the major anthocyanin (CYA-3-O-GluRut). Following MC supplementation plasma CYA-3-O-GluRut increased (Pâ<â0.05), with a greater uptake in the 60âmL dose found at 1âh. Serum urate was decreased (Pâ<â0.001) with a peak change (% of baseline) of 178âµmolâLâ1 (36%) at 8âh; urinary urate excretion (Pâ<â0.05) was increased, peaking at 2âh (178âµMolâmMol creatinineâ1 [250%]). Serum hsCRP (Pâ<â0.001) was decreased with peak decrements of 3.19âmgâLâ1 (29%).These data show that MC impacts upon the activity of uric acid and lowers hsCRP, previously proposed to be useful in managing pathological conditions such as gouty arthritis; the findings suggest that changes in the observed variables are independent of the dose provided.
[Journal of functional foods]
2017/US/US2017_3.rdf
Two doses (30 and 60âmL) of Montmorency tart cherry concentrate (MC) were used to investigate their impact on physiological indices of uric acid activity, inflammation and the bioavailability of the major anthocyanin (CYA-3-O-GluRut). Following MC supplementation plasma CYA-3-O-GluRut increased (Pâ<â0.05), with a greater uptake in the 60âmL dose found at 1âh. Serum urate was decreased (Pâ<â0.001) with a peak change (% of baseline) of 178âµmolâLâ1 (36%) at 8âh; urinary urate excretion (Pâ<â0.05) was increased, peaking at 2âh (178âµMolâmMol creatinineâ1 [250%]). Serum hsCRP (Pâ<â0.001) was decreased with peak decrements of 3.19âmgâLâ1 (29%).These data show that MC impacts upon the activity of uric acid and lowers hsCRP, previously proposed to be useful in managing pathological conditions such as gouty arthritis; the findings suggest that changes in the observed variables are independent of the dose provided.
